Top 50 Biotech Angel Investors in United Kingdom (October 2023)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Jonathan Milner
Angel
|
25 | United Kingdom, United States, Canada | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $430k–$50M |
|
Nadav Rosenberg
Angel
|
5 | United Kingdom, Israel, Singapore | Seed, Pre-Seed, Series A | Biotechnology, Artificial Intelligence, Pharmaceutical | $2M–$2M |
|
Darrin Disley
Angel
|
4 | United Kingdom | Seed, Series A | Biotechnology, Health Care, Big Data | $430k–$3.7M |
|
DrPano Kroko Churchill
Angel
|
3 | United Kingdom | Angel, Series A | Health Care, Therapeutics, Biotechnology | $150k–$430k |
|
Jude Gomila
Angel
|
3 | United States, United Kingdom, Canada | Seed, Pre-Seed, Angel | Software, Biotechnology, Information Technology | $190k–$3.1M |
|
Stefano Bernardi
Angel
|
3 | Italy, France, Norway | Seed, Pre-Seed | Software, Biotechnology, Cryptocurrency | $2M–$2M |
|
Peder Nielsen
Angel
|
3 | United Kingdom | Seed | Biotechnology, Machine Learning | |
|
Ian Hogarth
Angel
|
3 | United Kingdom, United States, Germany | Seed, Pre-Seed, Series A | Software, E-Commerce, Health Care | $123k–$12M |
|
Milad Alucozai
Angel
|
3 | United States, Canada, United Kingdom | Seed, Series A, Pre-Seed | Biotechnology, Health Care, Medical | $91k–$60M |
|
Serge Chiaramonte
Angel
|
2 | United Kingdom, United States, China | Seed, Pre-Seed, Series A | FinTech, Financial Services, E-Commerce | $1.2M–$4.1M |
|
Paul Wicks
Angel
|
2 | United Kingdom | Seed, Series A | Real Time, Marketplace, Biotechnology | |
|
Paul Forster
Angel
|
2 | United Kingdom, Germany, Spain | Seed, Series A, Pre-Seed | Software, FinTech, Financial Services | $750k–$9.9M |
|
Nadav Ben-Chanoch
Angel
|
2 | United States, United Kingdom, France | Seed, Pre-Seed | Software, Information Technology, Health Care | $100k–$5M |
|
Jon Oringer
Angel
|
2 | United States, France, United Kingdom | Seed, Pre-Seed | Software, Information Technology, E-Commerce | $80k–$9.3M |
|
Nicholas Edwards
Angel
|
2 | United Kingdom | Seed | Medical, Health Care, Life Science | |
|
Charlie Songhurst
Angel
|
2 | United States, United Kingdom, Germany | Seed, Pre-Seed, Series A | Software, Information Technology, Artificial Intelligence | $360k–$18M |
|
Gilad Engel
Angel
|
2 | France, United Kingdom | Seed, Pre-Seed | Analytics, Biotechnology, Financial Services | |
|
Nick Boyle
Angel
|
2 | United Kingdom | Seed | Biofuel, Agriculture, Artificial Intelligence | $3M–$3M |
|
Inaki Berenguer
Angel
|
2 | Spain, United States, United Kingdom | Seed, Angel, Pre-Seed | E-Commerce, FinTech, Enterprise Software | $215k–$9M |
|
Mark Evans
Angel
|
2 | United Kingdom, United States, The Netherlands | Series A, Seed | Software, E-Commerce, Health Care | |
|
Chris Mairs
Angel
|
2 | United Kingdom, United States | Seed, Pre-Seed, Angel | Software, FinTech, Financial Services | $492k–$1M |
|
Edward Lando
Angel
|
2 | United States, France, United Kingdom | Seed, Pre-Seed | Software, Information Technology, Health Care | $100k–$4.5M |
|
Tim Dempsey
Angel
|
2 | United Kingdom | Seed, Series A | Software, SaaS, Information Technology | |
|
Ed Parkinson
Angel
|
2 | United Kingdom | Seed | Software, Health Care, Life Science | |
|
Jim Mellon
Angel
|
2 | United States, United Kingdom, Israel | Series A, Seed | Biotechnology, Health Care, Food and Beverage | $503k–$20M |
|
Ariel Poler
Angel
|
2 | United States, Mexico, United Kingdom | Seed, Series A, Angel | Software, Social Media, Internet | $1M–$7M |
|
Pratima Aiyagari
Angel
|
2 | United Kingdom, France, Croatia | Pre-Seed, Seed, Series A | Analytics, Information Technology, Software | |
|
Patrick Pichette
Angel
|
2 | United Kingdom, Germany, United States | Seed, Series B, Series A | Artificial Intelligence, Machine Learning, Software | |
|
Hugh Grant
Angel
|
2 | United Kingdom | Seed | Biotechnology, Machine Learning | |
|
Jan Hruska
Angel
|
2 | United Kingdom | Seed | Medical, Health Care, Life Science | |
|
Margaret Georgiadis
Angel
|
1 | United States, United Kingdom | Seed, Series A, Series B | Health Care, Apps, Wellness | |
|
Michelle Tempest
Angel
|
1 | United Kingdom | Seed, Series A | Health Care, Science/Engineering, Gaming | |
|
Taz Patel
Angel
|
1 | United States, United Kingdom | Seed, Series A | SaaS, Information Technology, Mobile | |
|
Justin Mateen
Angel
|
1 | United States, Mexico, Brazil | Seed, Series A, Pre-Seed | Software, Commerce/Shopping, Financial | $400k–$14M |
| Bryan Meehan | 1 | Seed, Angel, Series A | Software, Sustainability, Data and Analytics | $2.7M–$6.2M | |
| Michail Eleftheriou | 1 | Seed | Software, Health Care, Biotechnology | $150k–$900k | |
|
Sam Fazeli
Angel
|
1 | United Kingdom | Post-IPO Equity | Education, Health Care, Biotechnology | |
|
Dave DeWalt
Angel
|
1 | United States, Israel, United Kingdom | Series A, Series C | Cyber Security, Security, Network Security | $9.5M–$11M |
|
Christine Soden
Angel
|
1 | United Kingdom | Post-IPO Equity | Education, Health Care, Biotechnology | |
|
Vishal Rao
Angel
|
1 | United States, India, Canada | Seed, Pre-Seed | Software, Artificial Intelligence, Information Technology | $22k–$4M |
|
Mark Bamforth
Angel
|
1 | United Kingdom, United States | Series A, Series B | Health Care, Science/Engineering, Biotechnology | $9.2M–$19M |
|
Mark McCamish
Angel
|
1 | United Kingdom | Seed | Medical, Biopharma, Biotechnology | |
|
David Rowan
Angel
|
1 | United Kingdom, Croatia, United States | Seed, Pre-Seed | Software, Artificial Intelligence, Information Technology | $1M–$2.4M |
|
Julien Codorniou
Angel
|
1 | France, United Kingdom, United States | Seed, Series A, Pre-Seed | Software, Apps, Commerce/Shopping | $125k–$25M |
|
Jon Moulton
Angel
|
1 | United Kingdom, Cyprus, Luxembourg | Seed, Series A | Financial Services, FinTech, Banking | $1.8M–$8.5M |
|
Simon Galbraith
Angel
|
1 | United Kingdom | Pre-Seed | Health Care, Biotechnology, Science/Engineering | |
|
Chris Paul
Angel
|
1 | United States, France, Portugal | Seed, Series A | Food and Beverage, Sports, Health Care | |
|
Sarah Howell
Angel
|
1 | United Kingdom | Post-IPO Equity | Education, Health Care, Biotechnology | |
|
Alice Zhang
Angel
|
1 | United States | Seed, Series A, Pre-Seed | Health Care, Science/Engineering, Biotechnology | $120k–$5.9M |
|
David Evans
Angel
|
1 | United Kingdom | Genetics, Biopharma, Biotechnology | ||
| Access all 50 angel investors in United Kingdom Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Canada
Investor stats
- Total investments: 44
- Round size: Seed $430k–$10M; Series A $1.8M–$18M; Series B $1.8M–$50M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
- PharmEnable — Designing the next generation of small molecule drugs. Replicating the specificity of biologics in the scalable form of a small molecule.
- Pencil Biosciences — Next Generation Genome Editing Tool
Nadav leads Taboola’s expansion and operations in Europe and Australia.Prior to joining Taboola, Nadav was a member of the founding team of Groupon UK & IR, taking part in building and managing Groupon’s business in the UK.Before joining Groupon, Nadav worked as a strategy consultant with McKinsey & Company in London.Nadav isbased in London and holds an MBA from INSEAD, France.
Show more...Investment focus
- Industry: Biotechnology, Artificial Intelligence, Pharmaceutical
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, Israel, Singapore
Investor stats
- Total investments: 13
- Round size: Pre-Seed $2M–$2M
- Lead/follow: 8% lead, 92% follow
Portfolio highlights
- thymia — Making mental health as objectively measurable as physical health.
- Exogene — Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.
- Loops — Loops is a no-code analytics platform that provides product and data teams with growth opportunities hidden in their data.
Darrin Disley is the CEO, Director & Investor at Mogrify. He attended University of Cambridge.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Big Data
- Stage:Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 4
- Round size: Seed $430k–$3.7M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- bit.bio — Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. Their mission is coding cells for health. To do so, we apply the principles of computation to biology. Bit.bio's current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. Thishas the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by the human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modeling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious, and driven by a common purpose.
- Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
- Desktop Genetics — Desktop Genetics is an international biotechnology company established in 2012 to help researchers discover and treat the root genetic causes of human disease. Today, Desktop Genetics is a recognised leader in genome editing technology, staffed by dedicated team of genome editing experts, bioinformaticians and data scientists, driven by thereal-world impact of CRISPR technology.They have invested four years developing their core technology, DESKGEN AI, trained on the largest database of genome editing data in the world. DESKGEN AI powers their flagship DESKGEN CRISPR Library product range, which enables the work of their pharma, biotech and academic customers working in drug discovery and functional genomics. Desktop Genetics' tools and technologies are used by over 1800 organisations all over the world, and their projects contribute directly to several key partnerships to bring CRISPR into the clinic. The company has received awards from Fast Company, Kairos 50 and SxSW Interactive.
Pano Kroko is a legendary entrepreneur, Angel, VC and PE investor in innovation towards solving big problems. His investment emphasis is on Life Sciences, Biotech, Therapeutics, Medicine, Internet, Mobile, Communications, Clean Technology, Renewable Energy, and Environmental Finance. We have a quarterly Business Plan competition for placementin our early stage start up accelerator in Seattle Washington. We also run a program in Washington DC, and we have an Innovation Master Class Startup Weekend that runs Ten times a year in Seattle, Beijing, Silicon Valley, and in major Universities around the world.The Accelerator in Seattle & Silicon Valley is called American Angels, and the Accelerator in Washington DC is named H2O and both accept business plans and great ideas with Founders, and Executive teams right now. We would like to see StartUps in all of our areas of focus as well as anything else that is great and promising to solve Big Problems. Parallel to this we also run the CEP - Clean Energy Program incubator in Oxford UK, and the Biotech accelerator for genetics, stem cell applications, genomics, medicine, pharma and telomeres research in Cambridge UK.For our more traditional VC and PE work in the US, the American Venture Company in the US and the Investment Bank Green Capital Inc in the UK and Europe. These are our conduits of support for companies and also the Green Bonds Investments Plc. All of our organizations act as levers of positive change for impact investing, and as corporate environmental investment responsibility -- within the Finance community.In Seattle and in Silicon Valley we run the Accelerator and Early Stage Investment firm AMERICAN ANGELS where we have monthly pitches and demos for new StartUps and we also run a CEO roundtable to help promising Entrepreneurial leaders to succeed.If you or your company is interested in cooperation, presenting, funding, deal syndication or simply for submission of Executive Summaries and Business Plans for early stage angel funding and/or inclusion in the H2O Incubator/Accelerator or the Clean Energy program and the Biotech incubator, please contact us herewith: Mr Ruddy Wallace: envpar [at] gmail.com
Show more...Investment focus
- Industry: Health Care, Therapeutics, Biotechnology
- Stage:Angel, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 3
- Round size: Angel $150k–$430k
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Amrit Advanced Biotech — Company working in Genetics, Telomeres health applications, cancer mitigation and lengthening of....
Jude Gomila is currently CEO and Founder of the startup Golden.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Pre-Seed, Angel
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 50
- Round size: Seed $1.2M–$3.1M; Angel $190k–$1.3M; Pre-Seed $1.2M–$2M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Parcha AI — Parcha is an AI-powered enterprise software that enables businesses to automate their scale compliance and operations.
- Monitaur — Reduce operational overhead, improve security, optimize performance, and deliver amazing customer experiences with our end-to-end, hybrid observability & APM platform built for decentralized apps and infrastructure.
- Gradia Health — Gradia is an integrated, concierge care platform designed for clinics to support patients with chronic conditions.
Stefano Bernardi is the Investment Director, Climate at Fondazione ENEA Tech.
Show more...Investment focus
- Industry: Software, Biotechnology, Cryptocurrency
- Stage:Seed, Pre-Seed
- Geography: Italy, France, Norway
Investor stats
- Total investments: 13
- Round size: Pre-Seed $2M–$2M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Freatic — We bridge the gap between individuals with untapped knowledge and actors who can take advantage of these opportunities.
- Eden Bio — Eden Bio is a biotech using machine learning to guide the genetic engineering of microorganism strain optimisation, improving protein yield.
- CaSRevolution — A novel disease-modifying approach against neurodegeneration
Peder Nielsen - Member of the Global Advisors Network @ Global Bio Fund
Show more...Investment focus
- Industry: Biotechnology, Machine Learning
- Stage:Seed
- Geography: United Kingdom
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.
Ian got a master's in machine learning at Cambridge and loves dystopian robot takeover narratives. Seven years ago, Ian realized being a choirboy came with no street cred, so he started DJing hip-hop, funk, drum & bass, and grime. Ian quit his job at Bain & Company, Singapore to start Songkick.
Show more...Investment focus
- Industry: Software, E-Commerce, Health Care
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 40
- Round size: Seed $1.5M–$12M; Pre-Seed $123k–$1.4M
- Lead/follow: 5% lead, 95% follow
Portfolio highlights
- Claimer — Claimer is a self-service application that gets credit claims done easily of money spent on research and development. Its platform empowers company owners and advisors to prepare their claims, without any specialist knowledge, no matter how big or small the claim. It also prepares and submits the amended tax return for free.Claimer was founded in2019 by Adam McCann and is headquartered in Croydon, United Kingdom.
- The Garden — The Garden is an online media company.
- Condense — Live-streamed volumetric video into game engines
Dr. Milad Alucozai is an Afghan-American neuroscientist, entrepreneur, biotech executive, and global investor with nearly two decades of experience in deep tech, primarily in life sciences. He pushes the boundaries of bioengineering and computational advancements, integrating machine learning and artificial intelligence into biology and medicine.With a strong commitment to commercializing transformative technologies and fostering startup ecosystems worldwide, he is a thought leader and formal mentor for entrepreneurs through organizations like Creative Destruction Lab and the Wyss Institute at Harvard Medical School.Currently, Milad is the head of Bio and Deep Tech at BoxOne Ventures, where he spearheads the firm’s investments in early-stage companies with breakthrough scientific ideas. With nearly 80 early-stage investments, they are recognized as one of North America’s most active venture firms. He is also a Venture Partner at Entrepreneur First, a global fund that has built over 500 companies from scratch with an enterprise value of $10bn. He supports founders with strategy, scaling, business development, securing growth capital, and leadership training, often being their first investor and guiding them from startup inception to IPOs or acquisitions.He started his career in translational neuroscience and multiphysics laboratories before transitioning into founding roles at biotech startups. He is part of the founding team at Mekonos, a San Francisco-based company creating a proprietary cell-engineering platform to support the future of cell and gene therapies. He was also part of the founding team at Corstem, which specialized in machine learning and artificial intelligence software and was later acquired by Circle Cardiovascular, a platform in over 1000 hospitals and more than 40 countries. At Accenture, Milad directed teams of data scientists, designers, and engineers in developing artificial intelligence platforms for global pharmaceutical companies and hospital networks.Milad serves as a Fellow in Healthcare Engineering at the Regenstrief Center. In 2020, he served as an External Advisor to AstraZeneca. He was recognized as a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine. He graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program. As a George J. Mitchell Scholar, he completed his master’s in Immunology and earned his doctorate from the Richard M. Fairbanks School of Public Health.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 47
- Round size: Seed $91k–$4.5M; Pre-Seed $107k–$1.4M; Series A $25M–$60M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- Arpeggio Bio — Arpeggio Biosciences leverages state of the art sequencing approaches coupled with powerful machine learning to uncover novel insights into a compound's biological mechanism of action.The company is diverse set of molecular biologists, computer scientists, and biotechnology enthusiasts passionate about understanding where, why, and howtherapeutics work.
- Future Fields — Future Fields Cellular Agriculture: Serum-Free Growth Media Supplements and Recombinant Proteins - Optimized for the Future of Food.
- Eigen Therapeutics — Eigen Therapeutics is a biotechnology company developing combination therapeutics for cancer. The company is in the research and development of synergistic therapies that improve efficacy while reducing the toxicity of small molecule therapies and immunotherapies, enabling physicians to get access to novel drugs in areas of unmet medical needs.
Serge Chiaramonte
Show more...Investment focus
- Industry: FinTech, Financial Services, E-Commerce
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, United States, China
Investor stats
- Total investments: 47
- Round size: Seed $1.2M–$4.1M; Series A $2.7M–$3.7M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Trezy — Trezy is smart & simple software the helps you manage your business with real-time finance insights & automated cash-flow forecasting.
- Basket — Basket lets you keep track of things you want to buy, automatically finding the best prices, saving you time and money. Say hello to your new shopping companion.
- Klasha — At Klasha, we're simplifying borderless payments for commerce in Africa. We help merchants worldwide sell online to Africa and receive payments in local African currencies while enjoying super fast last-mile delivery to customers across the continent.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Paul is a neuropsychologist and expert in digital health, clinical trials, and patient centricity. For 13 years he led the R&D team at PatientsLikeMe, an online community for over 700,000 people living with medical conditions. Specialising in clinical research using the Internet, Paul shaped the scientific validity of the platform in generatinginsights from patient-generated health data, leading to over 110 studies including a patient-driven observational trial of lithium in ALS, numerous patient-reported outcome measures, a “dose-response” curve for the benefits of friendship between patients, and methods for patient-centered and virtual clinical trial designs.He sits on the editorial boards of the BMJ, BMC Medicine, JMIR, Digital Biomarkers and The Patient. Prior to joining PatientsLikeMe, Paul worked at the Institute of Psychiatry (King’s College London) studying cognition and neuroimaging in ALS, with a postdoc in psychological consequences of Parkinson’s disease.His work has been profiled by the BBC, NPR, CNN, BBC Radio 4, the Wall Street Journal, and the New York Times. In 2011 he was awarded MIT Technology Review’s TR35 “Humanitarian of the Year” award, recognized as a TED Fellow in 2012, and joined the inaugural FLIER Program at the Academy of Medical Sciences in 2019.
Show more...Investment focus
- Industry: Real Time, Marketplace, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Sano Genetics — The future of precision medicine is here. Deep dive into your DNA & contribute to the latest research opportunities. Discover Sano Genetics.
Paul Forster
Show more...Investment focus
- Industry: Software, FinTech, Financial Services
- Stage:Seed, Series A, Pre-Seed
- Geography: United Kingdom, Germany, Spain
Investor stats
- Total investments: 57
- Round size: Seed $750k–$4.5M; Pre-Seed $1M–$1.6M; Series A $2.9M–$9.9M
- Lead/follow: 2% lead, 98% follow
Portfolio highlights
- Outverse — A community platform that's easier to use, better organised and designed for real interaction.
- CultureAI — Measure and improve human cyber risks and security behaviours to prevent security incidents. Go beyond security awareness training, start your free trial today.
- finway — finway provides financial guidence to SMEs, plan & control all expenses and budgets in one tool.
Nadav Ben-Chanoch - Partner @ Pareto Holdings
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Pre-Seed
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 147
- Round size: Seed $120k–$5M; Pre-Seed $100k–$1.9M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Swaap — We build the market-neutral AMM protocol.
- micro1 — We help companies hire and manage the best software engineers easily.
- Skedway — Every work experience should be great! Skedway is the complete platform to optimize the hybrid work experience.
Jon Oringer is the founder and chairman of Shutterstock.
Show more...Investment focus
- Industry: Software, Information Technology, E-Commerce
- Stage:Seed, Pre-Seed
- Geography: United States, France, United Kingdom
Investor stats
- Total investments: 106
- Round size: Seed $326k–$9.3M; Pre-Seed $80k–$3.2M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Skedway — Every work experience should be great! Skedway is the complete platform to optimize the hybrid work experience.
- Zamp — We give you freedom from sales tax! Eliminate the need to learn, manage or touch any part of the sales tax compliance process.
- NewHomesMate (formerly Propertymate) — Find, compare and buy a new construction home - all in one place.
Nick serves as the Chairman of Prescient’s Board of Directors. He holds a degree in physiological sciences from The Queen’s College, University of Oxford, and completed his training in clinical medicine (BM, BCh) at Green College (now Green Templeton College), University of Oxford. Nick practiced in the areas of cardiology and general surgerybefore joining Andersen Consulting (now known as Accenture), eventually becoming the global leader of Accenture’s pharmaceutical R&D business during his 18-year tenure. In 2005, he founded Kinapse to provide consulting and outsourcing services to the pharmaceutical industry. Nick served as Kinapse’s Chairman until the company was sold to HgCapital in early 2016.
Show more...Investment focus
- Industry: Medical, Health Care, Life Science
- Stage:Seed
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Oxford Medical Products — Oxford Medical Products is a UK-based biotechnology start-up revolutionising the weight-loss treatment space with its hydrogel-based technology.
Charles Songhurst is a founding partner of Katana Capital, a long-short equity hedge fund. He also runs the Songhurst Group, which holds assets in a variety of private companies.Charles ran corporate strategy for Microsoft and focused on partnering and M&A. He was involved in the Yahoo acquisition and commercial deal, and the Skypeacquisition. Before running corporate strategy, Charles was focused on the emergence of Google and the growth of the search industry.Prior, Charles was an analyst at McKinsey & Company in London. Charles received a bachelor’s degree from Oxford University in politics, philosophy, and economics.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 137
- Round size: Seed $1M–$6.4M; Pre-Seed $360k–$3.8M; Series A $2.5M–$18M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Hubflo — Hubflo is building an all-in-one work OS to help small businesses manage their business. Instead of having 10 complicated and expensive pieces of software, Hubflo offers SMB everything they need to run their business (CRM, projects, invoicing, expenses...) in a single comprehensive, simple and affordable platform.
- Story Protocol — Story Protocol is building open IP infrastructure to grow the creativity of the internet era.
- Borderless — Borderless is a workforce migration platform.It offers automation solutions that focuses on all aspects of hiring and onboarding of foreign workers, including recruitment, immigration, relocation, and compliance.
Gilad Engel - Partner @ Target Global
Show more...Investment focus
- Industry: Analytics, Biotechnology, Financial Services
- Stage:Seed, Pre-Seed
- Geography: France, United Kingdom
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Joe — Joe is an financial service that reimburses and allows ALL expenses to be paid in several installments.
- Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
In 2010, Nick founded Lightsource Renewable Energy, then just a six-person start-up, which quickly grew over 5 years to become Europe’s largest solar developer and operator and a recognised global leader. In his role as Group CEO, Nick’s dynamic leadership and vision has driven the company to tremendous success and in December 2017, Lightsourceannounced a strategic partnership with BP which has committed aggressively to accelerate the low carbon transition. The company has rebranded to Lightsource BP in affirmation of this powerhouse commitment which is set to shape the future of global energy delivery. Nick previously sat at Board and Senior Director level in a number of leading retail financial service companies. Throughout his career, Nick has always been recognised for his entrepreneurial skill and success in pairing retail financial products with low-risk, predictable investments.
Show more...Investment focus
- Industry: Biofuel, Agriculture, Artificial Intelligence
- Stage:Seed
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Round size: Seed $3M–$3M
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- Better Origin — At Better Origin, our mission is to fix the broken food chain by converting waste into high-value insect products.
- Better Origin — At Better Origin, our mission is to fix the broken food chain by converting waste into high-value insect products.
Inaki Berenguer is the President and Co-founder at iPronics Programmable Photonics.
Show more...Investment focus
- Industry: E-Commerce, FinTech, Enterprise Software
- Stage:Seed, Angel, Pre-Seed
- Geography: Spain, United States, United Kingdom
Investor stats
- Total investments: 17
- Round size: Seed $215k–$9M; Angel $236k–$500k
- Lead/follow: 12% lead, 88% follow
Portfolio highlights
- Paack — Find the ideal delivery solution to integrate to your e-commerce. We adapt to your retail, offering your customer an amazing delivery experience.
- Libera Bio — Libera Bio is a biopharmaceutical company devoted to the development of a new class of therapeutics to address unmet medical needs in cancer
- Mable (Neurolytic Healthcare) — Neurolytic Healthcare provides personalized medicine for neurological conditions. Neurolytic Healthcare collects and extracts insights from a combination of genetic and biomarker data to enhance diagnosis and help clinicians decide on optimal treatment strategies for neurological conditions.The company delivers digitally and genomically-drivenmedical devices to improve the current treatment of migraine and other neurological disorders, including a diagnostic support tool, pharmacogenetic test, and a mobile app for migraine event prediction.
Mark is currently a Founding Partner and LP and Investment Committee member at Kindred Capital, a European Seed-Stage Venture fund, based in London. He was a General Partner at Balderton Capital/ Benchmark Europe from 2002 through 2015, and an EIR at Benchmark Capital in 1999/2000.He spent the prior 15 years @ Goldman Sachs, where hewas a General Partner and Management Committee member. He studied Economics at both University of Oxford and Queen's University in Canada.
Show more...Investment focus
- Industry: Software, E-Commerce, Health Care
- Stage:Series A, Seed
- Geography: United Kingdom, United States, The Netherlands
Investor stats
- Total investments: 37
- Lead/follow: no public data
Portfolio highlights
- ONI — ONI is a pioneer of super-resolution microscopy, making this advanced technology accessible to new generations of researchers. The Nanoimager, the world's first benchtop sized super-resolution microscope, delivers a step change in usability and precision. This, together with our next-generation consumable products will empower academicresearchers, clinicians and scientists to on a path to discovery.The microscope offers easy access to a range of super-resolution techniques including dSTORM and PALM, as well as smFRET, single-particle tracking and confocal.The company's achievements have been recognised by FastTrack100 who named ONI on their 2018 list of 10 Disruptors to Watch and ONI won Best Business Start-up at the 2018 IOP Awards. More and more life science researchers and pharma companies are taking an interest in ONI and it now has customers using its products in leading laboratories across the globe, including the Universities of Oxford, Cambridge and Harvard.ONI has a restless enthusiasm to make the world a better place. Our ambition is to bring super-resolution fluorescence imaging to a new community of researchers and we are removing barriers to make science more effective, accessible and affordable. Our vision is to accelerate scientific discovery and fight disease by enabling everyone to visualize, understand and share the microscopic details of life.
- Ufonia — Ufonia is replacing routine patient healthcare interactions with next-generation automated phone calls.
- Arctoris — Arctoris is a platform company headquartered in Oxford, with its US operations based in Boston and its APAC operations based in Singapore. Arctoris developed and operates a unique drug discovery platform powered by advanced robotics and data science combined with an experienced team of biotech & pharma veterans. Arctoris actively pursuesseveral drug discovery programs in oncology and neuro, while also providing access to its platform to select biotech and pharma partners. Arctoris' approach of data-driven drug discovery leads to higher chance of success, and an accelerated progression of programs towards the clinic.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Chris Mairs - Venture Partner @ Entrepreneur First
Show more...Investment focus
- Industry: Software, FinTech, Financial Services
- Stage:Seed, Pre-Seed, Angel
- Geography: United Kingdom, United States
Investor stats
- Total investments: 17
- Round size: Seed $492k–$1M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Pathway — LLM-enabled financial research at the speed of thought.
- Statement — Find the right card machine for your business, with good rates and the best features. Search the top providers in minutes, including Worldpay, Barclaycard, Tyl and Teya.
- Borderless — Borderless is a workforce migration platform.It offers automation solutions that focuses on all aspects of hiring and onboarding of foreign workers, including recruitment, immigration, relocation, and compliance.
Edward Lando is the Managing Partner at Pareto Holdings.
Show more...Investment focus
- Industry: Software, Information Technology, Health Care
- Stage:Seed, Pre-Seed
- Geography: United States, France, United Kingdom
Investor stats
- Total investments: 221
- Round size: Seed $321k–$4.5M; Pre-Seed $100k–$1.9M
- Lead/follow: 1% lead, 99% follow
Portfolio highlights
- micro1 — We help companies hire and manage the best software engineers easily.
- Skedway — Every work experience should be great! Skedway is the complete platform to optimize the hybrid work experience.
- NewHomesMate (formerly Propertymate) — Find, compare and buy a new construction home - all in one place.
Tim Dempsey is a Managing Partner at Epiphany Capital. He graduated from the University of Manchester.
Show more...Investment focus
- Industry: Software, SaaS, Information Technology
- Stage:Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 16
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- Lunio — Drive performance marketing efficiency by cutting out invalid traffic across all paid marketing channels. Reach more users with the same ad spend.
- Mitra bio — We are transforming skin-care by approaching ageing as a disease to be fought. We are developing a genetic and epigenetic discovery platform to help skincare companies find and develop new compounds that actually fight the root cause of skin ageing.
- PPC Protect — Drive performance marketing efficiency by cutting out invalid traffic across all paid marketing channels. Reach more users with the same ad spend.
Ed Parkinson
Show more...Investment focus
- Industry: Software, Health Care, Life Science
- Stage:Seed
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- Antiverse — Designing biologics for 100 challenging targets
Jim Mellon is an international investor with interests in several industries. After leaving Oxford, where he studied PPE, (Philosophy, Politics and Economics) he worked in Asia and the United States for two fund management companies, GT and Thornton, before establishing his own business in 1991. His business operations include two components, alisted fund management company called Charlemagne Capital, and an Asian mining group, Regent Pacific.In addition, Mr. Mellon is Co-Chairman of West African Minerals Corporation and Regent Pacific Group. He is on the board of a number of public quoted companies, including Brazilian Gold Corporation, Charlemagne Capital Limited, Manx Financial Group, Plethora Solutions, Polo Resources, Port Erin Biophara Investments Limited, and the Speymill plc. He is the life tenant of a trust which owns the Burnbrae Group, which has substantial assets in the biotechnology, financial services, property, mining and leisure sectors. Mr. Mellon spends most of his time working on startup ideas and investing. His book, “Wake Up!” was published in 2005; his second book "10 Investments for the Ten Years Ahead" was published in 2008. In 2012, he co-wrote "Cracking the Code" which focuses on the biotechnology sector and how to profit from it. Mr. Mellon lives in the Isle of Man, Brussels and Ibiza and is an honorary fellow of Oriel College, Oxford.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Food and Beverage
- Stage:Series A, Seed
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 26
- Round size: Seed $503k–$20M; Series A $2.8M–$4.3M
- Lead/follow: 42% lead, 58% follow
Portfolio highlights
- Amy — Amy collects and analyzes information from all over the web and provides actionable insights about your leads, prospects and clients, all in one click.
- Monaco Foundry — We are a team of Serial Entrepreneurs, former Senior Government Advisors and Fortune 500 Executives. A global venture accelerator that invests in early to mid-stage companies and their growth through a unique sweat equity model.
- The Duppy Share — The Duppy Share Caribbean Rum is the best rum for cocktails, mixed drinks and rum gifts. Try all our rum recipes, from rum and ginger to dark rum punch.
Ariel Poler is the Co-Founder of Reveri Health. Ariel is an Internet entrepreneur, mentor, and investor. He was the founder of IPRO, the first web analytics company, and of Topica, one of the first email communities. Ariel was a board member of Kana Software, LinkExchange, Odeo, LOLapps, and StumbleUpon. He currently serves on the boards of FreedomFinancial Network, MixTent, Strava, and Scan Inc. Ariel’s angel investments include AdMob, Flixster, Slideshare, Xobni, RockYou, and Outright, BrightRoll, Instructables, Causes, Kongregate and NexTag. Ariel holds a B.S. in Mathematics with Computer Science from MIT and an MBA from Stanford University. He is originally from Venezuela and lives in San Francisco with his wife and three children.
Show more...Investment focus
- Industry: Software, Social Media, Internet
- Stage:Seed, Series A, Angel
- Geography: United States, Mexico, United Kingdom
Investor stats
- Total investments: 44
- Round size: Seed $1.1M–$7M; Angel $1M–$1.7M; Series A $2.6M–$5M
- Lead/follow: 5% lead, 95% follow
Portfolio highlights
- Reloadly — Reloadly is the #1 mobile top-up platform when it comes to developer-friendly technology. With our API and a few lines of code, you can easily integrate mobile top-up features into your website or mobile app.
- Openlytics — Openlytics is a visual analytics platform. It allows Data Workers to create pipelines for data transformation and analysis, in a visual way. Our mission is to empower everyone in the organization to solve data problems, without waiting for developers.Openlytics is an early-stage company, looking to build a founding team that can shape thedirection of the product. We’re seed-funded, remote-first, and hiring.If you're interested in learning more, email us at hello@openlytics.io.
- humm — humm harnesses cutting-edge neuroscience into products that allow people to learn faster and perform better.humm is working to bring the incredible results of neuroscience research out of the lab and into non-invasive wearables that improve the quality of life for everyday people. Our first product is a clinically validated patch that you wearfor 15 minutes to get up to 90 minutes of improved working memory, by gently stimulating the signals in the part of the brain that controls your executive thinking. humm improves your ability to learn and be at your best, allowing people to reconnect with the joy of learning and challenge themselves to continue growing at any stage of life, whether it's for work or personal enjoyment!
Pratima is a Venture Partner at Nauta Capital and is based in London. At Nauta, Pratima focuses on enterprise software and deep tech domains.Pratima has 18+ years of professional experience. She is a software developer by background and spent several years in Silicon Valley working on developing intelligent network services in the networkmanagement domain. Pratima joins Nauta from US-based cybersecurity-focused investment firm Paladin Capital. Previously, Pratima led investments and acquisitions at Cisco Corporate Development in Europe with a specific focus on ML/AI, Enterprise Collaboration and Silicon. During her investment career, Pratima led an investment or held board seats in Aimotive, Adbrain, Evrythng, Secure Code Warrior, decentriq, Dashbird, and several fund investments. She also managed investments in several companies including Behaviosec, Italtel, ip.access, and Corvil.Pratima received her MBA from INSEAD in France and an MS in computer science from the Virginia Polytechnic Institute and State University in the US. Pratima is a co-author of a US patent in the area of network device clusters and high availability.
Show more...Investment focus
- Industry: Analytics, Information Technology, Software
- Stage:Pre-Seed, Seed, Series A
- Geography: United Kingdom, France, Croatia
Investor stats
- Total investments: 8
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
- NetBird — Wiretrustee is an open-source VPN platform built on top of WireGuard® making it easy to create secure private networks for your organization or home. It requires zero configuration effort leaving behind the hassle of opening ports, complex firewall rules, VPN gateways, and so forth.
- Treblle — Treblle is a lightweight SDK that helps Engineering and DevOps teams build, ship & maintain REST based APIs faster
Patrick Pichette currently Board Member at LightSpeed and Twitter. He is a former Google's chief financial officer, where he started in June of 2008. He has nearly 20 years of experience in financial operations and management in the telecommunications sector, including seven years at Bell Canada, which he joined in 2001 as executive vicepresident of planning and performance management.During his time at Bell Canada, he held various executive positions, including CFO from 2002 until the end of 2003, and was instrumental in the management of the most extensive communications network in Canada and its ongoing migration to a new national IP-based infrastructure.Prior to joining Bell Canada, Patrick was a partner at McKinsey & Company, where he was a lead member of McKinsey's North American Telecom Practice. He also served as vice president and chief financial officer of Call-Net Enterprises, a Canadian telecommunications company.Patrick earned a bachelor's degree in business administration from UniversitA© du Quebec A MontrA©al. He holds a master's degree in philosophy, politics, and economics from Oxford University, where he attended as a Rhodes Scholar. He also serves on the board of Engineers Without Borders (Canada).
Show more...Investment focus
- Industry: Artificial Intelligence, Machine Learning, Software
- Stage:Seed, Series B, Series A
- Geography: United Kingdom, Germany, United States
Investor stats
- Total investments: 19
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- Apheris — Build ML-powered products using data that spans organizational or geographical boundaries, while ensuring compliance with regulation.
- Unlikely AI — We are pioneering safe, trustworthy and powerful artificial intelligence
- Vay — Vay is a leading teledriving company that aims to launch a unique, affordable, and sustainable door-to-door mobility service.
Hugh Grant is President and Chief Executive Officer at Monsanto.
Show more...Investment focus
- Industry: Biotechnology, Machine Learning
- Stage:Seed
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.
Jan Hruska
Show more...Investment focus
- Industry: Medical, Health Care, Life Science
- Stage:Seed
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Oxford Medical Products — Oxford Medical Products is a UK-based biotechnology start-up revolutionising the weight-loss treatment space with its hydrogel-based technology.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Margaret Georgiadis currently works as CEO-Partner and Co-Founder for Flagship Pioneering. She previously worked at General Catalyst as Endurance Partner In Residence. Margaret Georgiadis attended Harvard University
Show more...Investment focus
- Industry: Health Care, Apps, Wellness
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom
Investor stats
- Total investments: 10
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- OneRoof — OneRoof is an app that helps meet people with similar interests living in your building and build new friendships. Communication should go further than a nod in the elevator.
- ShareWell — Struggling with mental health issues? ShareWell provides online peer support, a proven mental health alternative for therapy. Get group support when you need it.
- Bridge Money — The path towards upward economic mobility.
Michelle Tempest
Show more...Investment focus
- Industry: Health Care, Science/Engineering, Gaming
- Stage:Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Daye — Organic, super absorbent, sustainable tampons for when your period is cramping your style. ProViotics for vaginal health. We deliver sustainable products that work hard to help you feel your best, whatever life brings.
- Medwise.ai — Medwise.ai is the Google for doctors.
Taz Patel is a serial entrepreneur with multiple exits over the past decade who continues to support the startup ecosystem via mentorship, advisory and investing. Most recently, Taz co-founded Captiv8, an Influencer marketplace and SaaS platform funded by Social Capital, Liquid 2, Visionnaire, Jason Calacanis, Cyan Banister and strategic Angels.Before this, Taz was the Chief Revenue Officer of Republic Project, a startup funded by Google Ventures and later acquired by DG Sizmek in 2013. Before that, Taz led monetization efforts at Showyou App funded by True Ventures that was acquired by Vevo in 2015. His knowledge in social marketing, mobile/video advertising, and SaaS/Marketplace businesses is a personal passion that stems from early sales leadership roles at Interclick and BlueLithium, both of which were acquired by Yahoo! for $270 Million in 2011 and $300 Million in 2007. A Chicago native, Taz studied at the University of California, Berkeley and currently lives with his wife, son and dog in San Francisco.
Show more...Investment focus
- Industry: SaaS, Information Technology, Mobile
- Stage:Seed, Series A
- Geography: United States, United Kingdom
Investor stats
- Total investments: 12
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- CloudAdmin.io — CloudAdmin is a cost-optimization platform that helps executives save money in hidden cloud instance buying options.
- Ampleforth — Ampleforth is the name of a character in George Orwell's 1984 who is responsible for translating poetry into Newspeak, a language designed to limit freedom of thought. When tasked to replace the word “God” in a Kipling poem, Ampleforth refuses, not out of righteousness, or subversiveness, but rather, a simple love for language and respect forthe truth. To Ampleforth, no other word makes sense in context and therefore no other word should replace it.
- Marigold Health — Marigold Health is an anonymous social network where people with mental health and substance use conditions support each other.
Justin Mateen is the Founder of Tinder, the world's largest dating platform. Founded in 2012, Tinder is the highest grossing app on Apple's app store since 2017 and was valued at over $40 Billion dollars in 2021. In 2021, Business Insider ranked Mateen as the best early stage investor in the US, placing him at the number 1 spot on thetop 100 list of US Seed Investors. In 2020, Forbes included Mateen on their list of the decade's top 10 tech entrepreneurs. Fast Company has listed him as one of the most creative people in business.
Show more...Investment focus
- Industry: Software, Commerce/Shopping, Financial
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Mexico, Brazil
Investor stats
- Total investments: 117
- Round size: Seed $841k–$7M; Pre-Seed $400k–$1M; Series A $4.7M–$14M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- Playdex — Playdex is an NFT gaming rental marketplace that seamlessly connects gamers, guilds, and NFT owners.
- Speak — People spend $90 billion a year on human english teachers that are expensive and ineffective. Speak offers a mobile app where you can have english conversations with your phone about real world scenarios like interviewing for a job or asking for directions. It uses speech recognition to identify english words through thick accents and teach peopleto speak more clearly. Meanwhile, it’s building a massive database of accented-english speech, which can be used to improve its system and other speech recognition systems. Speak’s team formerly built accent detection systems and sold Flashcards+ to Chegg. Though AI translation might reduce the need for people to know other languages, speaking English remains a valuable skill people are willing to pay for.
- Quicklly — Find local Grocery Stores & Restaurants online on Quicklly. Buy Groceries & Food online and get it delivered to your doorstep. Enjoy Free & Same Day Delivery.
Chief Executive Officer @ Blue Bottle Coffee
Show more...Investment focus
- Industry: Software, Sustainability, Data and Analytics
- Stage:Seed, Angel, Series A
Investor stats
- Total investments: 8
- Round size: Seed $2.7M–$6.2M
- Lead/follow: 0% lead, 100% follow
Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed
Investor stats
- Total investments: 2
- Round size: Seed $150k–$900k
- Lead/follow: 0% lead, 100% follow
Sam Fazeli is the Non Executive Director at Arecor Limited.
Show more...Investment focus
- Industry: Education, Health Care, Biotechnology
- Stage:Post-IPO Equity
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Arecor — Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides.In addition toits internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.
David G. DeWalt is the Founder and Managing Director of Dave DeWalt. He joined AllegisCyber Capital as a Managing Director in 2017. Dave is a renowned cybersecurity executive, having taken cyber industry leader FireEye public (Chairman & CEO) and served as the CEO of both McAfee and Documentum.He is a member or leader of six boards ofdirectors, including ForgeRock, ForeScout, Phantom Cyber, and OPTIV, and serves as the Vice Chairman of Delta Airlines. Dave consults regularly with government, industry players, and the corporate Board of Directors on matters related to cybersecurity policy, technology, and strategy.He holds a B.S. in computer science from the University of Delaware.
Show more...Investment focus
- Industry: Cyber Security, Security, Network Security
- Stage:Series A, Series C
- Geography: United States, Israel, United Kingdom
Investor stats
- Total investments: 19
- Round size: Series A $9.5M–$11M
- Lead/follow: 74% lead, 26% follow
Portfolio highlights
- Callsign — Marking a new era in passive authentication, fraud prevention and intelligence. We make digital identity simple and more secure.
- RapidSOS — RapidSOS securely links life-saving data from connected devices, apps and sensors to safety agents, 911 and first responders globally.
- Instant Channel — Instant Channel, Inc. is an advertising and marketing company that provides email marketing and communications services in the State of California.
Christine Soden is the Non-Executive Director at Arecor.
Show more...Investment focus
- Industry: Education, Health Care, Biotechnology
- Stage:Post-IPO Equity
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Arecor — Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides.In addition toits internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.
Advisory CTO and Angel Investor
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Pre-Seed
- Geography: United States, India, Canada
Investor stats
- Total investments: 66
- Round size: Seed $220k–$4M; Pre-Seed $22k–$3M
- Lead/follow: 2% lead, 98% follow
Portfolio highlights
- Berri AI — A website made with Typedream.
- Anarchy — Anarchy builds a cloud platform for AI pioneers to build LLM tools augmented with external interactivity.
- Consensus — Consensus uses AI to extract and summarize scientific insights from peer-reviewed sources. For any question, what's the Consensus?
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Mark Bamforth is the Operating Partner at Ampersand Capital Partners.
Show more...Investment focus
- Industry: Health Care, Science/Engineering, Biotechnology
- Stage:Series A, Series B
- Geography: United Kingdom, United States
Investor stats
- Total investments: 9
- Round size: Series A $9.2M–$19M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- Dxcover — Dxcover are a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases to improve survival and quality of life.
- PneumoWave — PneumoWave aims to transform the way patients with respiratory conditions manage their health and live their lives. Contact us to learn more!
- Talking Medicines — We connect medicines with their global digital patient voice. The smart way to understand patients.
Dr. McCamish is President and Chief Executive Officer of IconOVir Bio. Previously he was President and Chief Executive Officer of Forty Seven, Inc. He led Forty Seven, Inc. during critical phases of clinical development to help patients defeat their cancer. This included growing from a valuation of $169 million as a private company through a SeriesB offering, Initial Public Offering, two secondary fund raises and finally the acquisition of Forty Seven by Gilead for $4.9 Billion.He is an international expert in biologic and biosimilars development and manufacturing. Mark is passionate about mentoring and developing people while focusing on meeting patient needs through efficient, commercially viable efforts. He is a senior executive with extensive experience at multiple companies including Abbott, Amgen, and Novartis/Sandoz. He led pioneering efforts in filing/launching biosimilars worldwide. He has demonstrated a commercial mindset in establishing research and development strategies leading to approvals and commercial success in multiple therapeutic areas and regulatory categories including biologics, biosimilars, drugs, devices, and medical foods.He received Bachelor’s and Master’s degrees from UCSB and, after completing his PhD in Human Nutrition from Penn State and MD from UCLA, he completed Residency and Fellowship Training at the University of California, Davis. He held professorships at UC Davis and The Ohio State University
Show more...Investment focus
- Industry: Medical, Biopharma, Biotechnology
- Stage:Seed
- Geography: United Kingdom
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Nemesis Bioscience — Nemesis Bioscience is a UK-based biopharmaceutical company developing products to resurrect anti-microbial therapies made ineffective by increasing microbial resistance. The company develops Nemesis Symbiotics that will make existing antibiotics work again, prevent the spread of resistance genes, and so also protect the efficacy of new antibiotics.The technology is applicable to all antibiotic classes, all known resistance mechanisms and all bacteria.Other applications include reduction of chemotherapeutic toxicity, inactivation of virulence factors, and in vivo synthesis of biofuels and therapeutics.The company was awarded the King’s College, Cambridge Entrepreneurship Award for 2014 and has filed patent applications internationally on its inventions.
David Rowan is editor of the UK edition of WIRED magazine, which won 2009 Launch of the David Rowan is Editor of the WIRED UK, the technology and trends magazine covering online brands, gadgets and the culture that surrounds them. David has reported on technology for The Times and Channel 4 News, the latter requiring him to illustrate the newiPod Video from the set of a porn shoot. He's also written for The Sunday Times and Telegraph Magazines, and edited the Guardian's on-line content. David has curated an exhibition of British creative talent at the Government's Cabinet Forum conference. He has also addressed the TEDs, and frequently contributes on Newsnight and the Today programme. He also writes a monthly column for GQ. David is in touch with many of the world's leading trend-setters and spotters. In presentations he looks at how the net is disrupting almost every sector, how apps change consumer behaviour and why 'social commerce' is killing traditional marketing. He reveals the 10 trends that will change your market in the next decade - and what you should be doing now to protect yourself.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Pre-Seed
- Geography: United Kingdom, Croatia, United States
Investor stats
- Total investments: 22
- Round size: Seed $1M–$2.4M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- EWOR — Build a successful company with EWOR
- Climate X — Climate X combines climate science and econometrics to deliver precise climate risk data without any black boxes.
- Rhizocore Technologies — We develop high-performance strains of locally-sourced mycorrhizal fungi to improve tree growth, tree health and tree resiliency. We offer a sustainable solution to increase forest yields whilst improving the ability of trees to sequester carbon.
Julien is an investor at Felix Capital where he focuses on SaaS (Worktech in particular) and gaming investments.Before joining Felix, Julien Codorniou spent 11 years at Facebook where he led the global platform partnerships team, helping Facebook partners to build, grow and monetize their mobile apps and games. From 2016 to 2021, he has beenserving as Vice President of Workplace. Under his leadership, Workplace went from 0 to 9 million paid subscribers at companies like Walmart, Grab, GSK, Nestlé, Chevron, MercadoLibre, ServiceNow, Astrazeneca, Lixil, Spotify, Save the Children and many more globally. Julien started his career in finance and before Facebook he was Director of Business Development at Microsoft Corp.Since 2012, Julien has served on the board of the French media group Le Monde. He is the co-author of the book: "The Kelkoo.com success story"published by Pearson in 2005.His former investments, as business angel include companies like TripleDot Studios, Bloom & Wild, Pigment, Xentral, Homesome, Olio, Peanut, Nabla, Curio, Linktree, Airlift Technologies and Sunday.He grew up in France and now lives in London with his wife and their two boys.
Show more...Investment focus
- Industry: Software, Apps, Commerce/Shopping
- Stage:Seed, Series A, Pre-Seed
- Geography: France, United Kingdom, United States
Investor stats
- Total investments: 41
- Round size: Seed $536k–$24M; Pre-Seed $125k–$1M; Series A $3.2M–$25M
- Lead/follow: 7% lead, 93% follow
Portfolio highlights
- 5Mins — 5Mins is the new microlearning platform that helps your employees build in-demand skills fast with AI-powered personalisation and advanced gamification.
- Indeez — Indeez is an European insurtech focused on everyday needs of platform workers, by providing them with better income protection.
- Sharpist — We offer personalized learning that will help people-centric organizations and teams grow throughout the challenges of today and tomorrow. Learn more!
Jon Moulton is a British venture capitalist. He is the founder and managing partner of the private equity firm Better Capital, and is the former managing partner of the private equity firm Alchemy Partners.
Show more...Investment focus
- Industry: Financial Services, FinTech, Banking
- Stage:Seed, Series A
- Geography: United Kingdom, Cyprus, Luxembourg
Investor stats
- Total investments: 18
- Round size: Seed $1.8M–$3.6M; Series A $4.9M–$8.5M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Pockit — Open a prepaid account in 3 minutes online or in-app, get your contactless prepaid card in 2 working days with no credit check.
- Hometree — Keep yourself warm with Hometree, and try our no price hike promise. Compare our different boiler & home cover plans to see how you can save.
- Hellas Direct — Hellas Direct is a digital-first, full-stack insurance company, empowered by cutting-edge technology and artificial intelligence. The Cyprus-based company is backed by a roster of leading investors, including Portag3, IFC (a member of the World Bank), Endeavor Catalyst, former Goldman Sachs economist Lord O’Neill and private equity veteran JonMoulton. Modelling itself on Amazon, Hellas Direct aims to disrupt the insurance value chain by adopting an extreme focus on operational excellence.
Simon is the joint founder and CEO of Redgate Software. Over the past 15 years, Simon has been part of Redgate’s growth from a 2 person firm operating out of a spare room to today’s 300 person outfit with hundreds of thousands of users. Although Simon’s responsibilities are primarily strategic, his background is technical with qualificationsincluding a PhD in physics from Cambridge University and former employment with Shell and ThornEMI.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Science/Engineering
- Stage:Pre-Seed
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- BoobyBiome — BoobyBiome uses specialist expertise and research to develop a probiotic supplement for infants with compromised microbiomes. We aim to promote healthy infant development by recreating the beneficial bacteria associated with breast milk.
- SysKit — SysKit is a software development company specializing in enterprise tools for SharePoint, Microsoft 365, Windows Server, Remote Desktop Services, Citrix.
Christopher Emmanuel Paul is an American professional basketball player for the Oklahoma City Thunder of the National Basketball Association.
Show more...Investment focus
- Industry: Food and Beverage, Sports, Health Care
- Stage:Seed, Series A
- Geography: United States, France, Portugal
Investor stats
- Total investments: 18
- Lead/follow: 17% lead, 83% follow
Portfolio highlights
- Scout - Make Money Moves — Our mission is to make investing fun, relatable, and safe. Scout is an investing platform that allows you to build investment portfolios aligned with your interests. Think: eco-friendly brands, Women-led companies, Bitcoin, and the most popular Gen Z stocks. With Scout, you choose what you invest in, and we risk-manage your portfolio so you caninvest safely.
- Buoy — Zero sugar liquid electrolytes and ionic trace minerals that blend with any beverage, even alcohol and coffee. No sugar, no stevia, no dextrose, no flavorings and no artificial ingredients. Gluten and major allergen free. Vegan and non-GMO.
- Mitchell & Ness — Mitchell & Ness Nostalgia manufactures and retails apparel and accessories for men and women. It focuses on offering consumers a range of licensed apparel from the NFL, NBA, NHL, and AFL; and non-licensed active wear. The company offers adjustables, banners and pennants, bottoms, buckets, fitted products, fleece products, jerseys, outerwear,shirts, slouch products, snapback products, and strapback products; and headwear, duffle bags, gloves, scarves, and socks.
Sarah Howell joined Arecor Limited as Chief Executive Officer in 2015.
Show more...Investment focus
- Industry: Education, Health Care, Biotechnology
- Stage:Post-IPO Equity
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Arecor — Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides.In addition toits internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.
CEO and Co-founder at Verge Genomics; Angel Investor in Tech-Enabled Bio
Show more...Investment focus
- Industry: Health Care, Science/Engineering, Biotechnology
- Stage:Seed, Series A, Pre-Seed
- Geography: United States
Investor stats
- Total investments: 15
- Round size: Seed $120k–$5.9M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Encellin — Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics. It has dedicated experts focused on the investigation and advancement of next-generation therapies. It aims to help patients with chronic diseases, starting with Type 1 diabetes. It was founded in 2016 and is headquartered in San Francisco, California.
- Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
- Arpeggio Bio — Arpeggio Biosciences leverages state of the art sequencing approaches coupled with powerful machine learning to uncover novel insights into a compound's biological mechanism of action.The company is diverse set of molecular biologists, computer scientists, and biotechnology enthusiasts passionate about understanding where, why, and howtherapeutics work.
David holds a Ph.D. in social psychology and is a Senior Manager of Customer Research at Microsoft. There he influences the design and positioning of Office 365, Cortana, and the Office Graph. David is the author of a new guide to behavioral design entitled Bottlenecks: Aligning UX Design with User Psychology based on the graduate classes heteaches at the University of Washington. Bottlenecks recounts case studies in which the psychological constrictions of attention, perception, memory, disposition, motivation, and social influence determined whether customers were receptive to digital innovations - or not.
Show more...Investment focus
- Industry: Genetics, Biopharma, Biotechnology
- Geography: United Kingdom
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Horizon Discovery — Horizon Discovery Group PLC is a UK life science company that uses gene editing and gene modulation platforms to produce cells, applying them in research and clinical applications that advance human health. The Company’s gene editing and gene modulation platform, are able to alter almost any DNA sequence or RNA transcription, has generated acatalogue of over 1,000,000 cell and reagent products that help researchers recapitulate the genetic and protein anomalies found in diseases like cancer. These models have been adopted by c12, 000 organizations to better understand of the predictors and drivers of disease and drug response, and by Horizon in a range of services offered to customers, as well as in the Company’s own research R&D pipeline.
FAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech Angel Investors in United Kingdom investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 48,091 angel investors investing in United Kingdom Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!